ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,431.60
-0.04%
US Tech 100
19,168.00
0.52%
다우존스 지수
38,589.16
-0.15%
Bitcoin
66,115.96
0.17%
Registration Strip Icon for discussion 같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Leap Therapeutics Inc (LPTX)

  7. Leap Therapeutics Inc (LPTX) 뉴스

LPTX

Leap Therapeutics (LPTX)

Leap Therapeutics Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:LPTX
일자시간출처헤드라인심볼기업
2024/05/2413:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:LPTXLeap Therapeutics Inc
2024/05/2405:25Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:LPTXLeap Therapeutics Inc
2024/05/1320:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPTXLeap Therapeutics Inc
2024/05/1320:00PR Newswire (US)Leap Therapeutics Reports First Quarter 2024 Financial ResultsNASDAQ:LPTXLeap Therapeutics Inc
2024/05/1319:50Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LPTXLeap Therapeutics Inc
2024/05/1106:01Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:LPTXLeap Therapeutics Inc
2024/05/1013:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:LPTXLeap Therapeutics Inc
2024/04/1121:30PR Newswire (US)Leap Therapeutics Announces $40 Million Private PlacementNASDAQ:LPTXLeap Therapeutics Inc
2024/03/1820:00PR Newswire (US)Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:LPTXLeap Therapeutics Inc
2024/02/0111:36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LPTXLeap Therapeutics Inc
2024/02/0111:36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LPTXLeap Therapeutics Inc
2024/02/0111:35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LPTXLeap Therapeutics Inc
2024/02/0111:35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LPTXLeap Therapeutics Inc
2024/02/0111:35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LPTXLeap Therapeutics Inc
2024/02/0111:34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LPTXLeap Therapeutics Inc
2024/02/0111:34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LPTXLeap Therapeutics Inc
2024/02/0111:34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LPTXLeap Therapeutics Inc
2024/01/3110:41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LPTXLeap Therapeutics Inc
2024/01/3110:39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LPTXLeap Therapeutics Inc
2024/01/2707:21Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:LPTXLeap Therapeutics Inc
2024/01/2407:28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPTXLeap Therapeutics Inc
2024/01/1707:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPTXLeap Therapeutics Inc
2024/01/1707:05PR Newswire (US)Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers SymposiumNASDAQ:LPTXLeap Therapeutics Inc
2024/01/0321:00PR Newswire (US)Leap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:LPTXLeap Therapeutics Inc
2024/01/0221:00PR Newswire (US)Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer PatientsNASDAQ:LPTXLeap Therapeutics Inc
2023/12/1306:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPTXLeap Therapeutics Inc
2023/12/1206:05PR Newswire (US)Leap Therapeutics to Present New Data from Part A of the DeFianCe Study of DKN-01 Plus Bevacizumab and Chemotherapy in Colorectal Cancer Patients at the 2024 ASCO Gastrointestinal Cancers SymposiumNASDAQ:LPTXLeap Therapeutics Inc
2023/11/2121:00PR Newswire (US)Leap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare ConferenceNASDAQ:LPTXLeap Therapeutics Inc
2023/11/1321:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPTXLeap Therapeutics Inc
2023/11/1321:00PR Newswire (US)Leap Therapeutics Reports Third Quarter 2023 Financial ResultsNASDAQ:LPTXLeap Therapeutics Inc
 검색 관련기사 보기:NASDAQ:LPTX

최근 히스토리

LSE
59YR
Investec Bnk 25
NYSE
TPVG
TriplePoint Venture Grow...
NYSE
CEY
Certegy
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유